Eli Lilly
-
EMA panel backs Eli Lilly’s Foundayo pill for obesity and type 2 diabetes
The once-daily orforglipron tablet would become the second oral GLP-1 drug in the EU after Novo Nordisk's Wegovy pill, with a European Commission decision expected within weeks.
